Aggressive polychemotherapy for acute myelofibrosis.
Acute myelofibrosis is a rare and still ill-defined disease. Based on morphological observation, immunophenotyping and ultrastructural analysis, we support the assumption that acute myelofibrosis is a malignant disorder mainly of the megakaryocytic lineage and is closely related to acute megakaryocytic/blastic leukaemia. Consequently, the 11 patients reported here were treated with aggressive polychemotherapy with combinations including daunorubicin and cytosine arabinoside and 6-thioguanin or VP16-213. 4 complete remissions, 2 partial remissions and 1 minor response were observed. Duration of aplasia was not significantly prolonged. These findings indicate that the use of aggressive polychemotherapy is feasible in acute myelofibrosis and results in a significant number of remissions.
Hertenstein
B
B
Abteilung Innere Medizin III, Medizinische Universitätsklinik Ulm, Fed. Rep. Germany.
Kurrle
E
E
Frickhofen
N
N
Heil
G
G
Heimpel
H
H
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004906:Erythrocyte Count; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008533:Megakaryocytes / Q000473:pathology; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D013866:Thioguanine / Q000008:administration & dosage / Q000627:therapeutic use*
D003561:Cytarabine; D013866:Thioguanine; D003630:Daunorubicin